Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | MMP1 | P03956 | 6/20 | 0.40 |
| ▸ | MMP9 | P14780 | 5/20 | 0.40 |
| ▸ | MMP2 | P08253 | 5/20 | 0.40 |
| ▸ | MMP12 | P39900 | 5/20 | 0.40 |
| ▸ | RXRA | P19793 | 1/20 | 0.38 |
| ▸ | RXRB | P28702 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | APP | P05067 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26740596 | 0.87 | MMP2 (0.53) | NPC1RAB9AMMP1MMP9MMP2 | |
| SCHEMBL30636845 | 0.86 | NPC1 (0.47) | NPC1RAB9AMMP1MMP9MMP2 | |
| SCHEMBL26630668 | 0.78 | ALDH1A1 (0.36) | RXRARXRBKMT2ALMNASMN1; SMN2 | |
| SCHEMBL1839413 | 0.77 | CA12 (0.49) | NPC1RAB9AKMT2AMEN1LMNA | |
| SCHEMBL2404923 | 0.75 | ALDH1A1 (0.50) | MMP1MMP9MMP12LMNASLC6A2 | |
| SCHEMBL2413275 | 0.72 | KDM4E (0.45) | NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL1837909 | 0.70 | ALDH1A1 (0.55) | NPC1RAB9AMMP1MMP9MMP2 | |
| SCHEMBL29217407 | 0.69 | KMT2A (0.76) | NPC1RAB9ARXRARXRBKMT2A | |
| SCHEMBL2705870 | 0.69 | TDP1 (0.54) | NPC1RAB9AMMP1MMP9MMP2 | |
| SCHEMBL16056361 | 0.69 | APP (0.39) | NPC1RAB9ARXRARXRBKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230357154-A1 | BUTYRYLCHOLINESTERASE COMPOUNDS AND USE IN DISEASES OF THE NERVOUS SYSTEM | TREVENTIS CORPORATION (US) | 2023-11-09 | — | — | US | disclosed |
| US-20230357154-A1 | BUTYRYLCHOLINESTERASE COMPOUNDS AND USE IN DISEASES OF THE NERVOUS SYSTEM | TREVENTIS CORPORATION (US) | 2023-11-09 | — | — | US | disclosed |
| US-20230357154-A1 | BUTYRYLCHOLINESTERASE COMPOUNDS AND USE IN DISEASES OF THE NERVOUS SYSTEM | TREVENTIS CORPORATION (US) | 2023-11-09 | — | — | US | disclosed |
| WO-2021026429-A1 | BUTYRYLCHOLINESTERASE COMPOUNDS AND USE IN DISEASES OF THE NERVOUS SYSTEM | TREVENTIS CORPORATION (US) | 2021-02-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230357154-A1 | BUTYRYLCHOLINESTERASE COMPOUNDS AND USE IN DISEASES OF THE NERVOUS SYSTEM | BCHE, ACHE, CHAT | NPC1 608/4885RAB9A 1521/4885MMP1 684/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.